当前位置：
X-MOL 学术
›
Biomater. Sci.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
A photothermal-hypoxia sequentially activatable phase-change nanoagent for mitochondria-targeting tumor synergistic therapy.
Biomaterials Science ( IF 5.8 ) Pub Date : 2020-04-06 , DOI: 10.1039/d0bm00003e Jia Qu 1 , Dengke Teng , Guoqing Sui , Shihui Guan , Yang Wang , Qimeihui Wang , Yuanqiang Lin , Haitao Ran , Zhigang Wang , Hui Wang
Biomaterials Science ( IF 5.8 ) Pub Date : 2020-04-06 , DOI: 10.1039/d0bm00003e Jia Qu 1 , Dengke Teng , Guoqing Sui , Shihui Guan , Yang Wang , Qimeihui Wang , Yuanqiang Lin , Haitao Ran , Zhigang Wang , Hui Wang
Affiliation
|
To enhance the specificity and efficiency of anti-tumor therapies, we have designed a multifunctional nanoparticle platform for photochemotherapy using fluorescence (FL) and photoacoustic (PA) imaging guidance. Nanoparticles (NPs) composed of a eutectic mixture of natural fatty acids that undergo a solid–liquid phase transition at 39 °C were used to encapsulate materials for the rapid and uniform release of the hypoxia-activated prodrug tirapazamine (TPZ) and the photosensitizer IR780, which targets the mitochondria of tumor cells and can be used to induce hypoxic cell death via photodynamic therapy and photothermal therapy. In vitro, the NPs containing TPZ and IR7890 exhibited appreciable cell uptake and triggered drug release when irradiated with a NIR laser. In vivo, photochemotherapy of the NPs achieved the best anti-tumor efficacy under PA and FL imaging guidance and monitoring. By combining IR780 mitochondria-targeting phototherapy with TPZ, we observed improved anti-tumor effectiveness and this has the potential to reduce the side effects of traditional chemotherapy. Herein, we demonstrate a new intracellular photochemotherapy nanosystem that co-encapsulates photosensitizers and hypoxia-activated drugs to enhance the overall anti-tumor effect precisely and efficiently.
中文翻译：
用于线粒体靶向肿瘤协同治疗的光热低氧顺序可激活相变纳米剂。
为了提高抗肿瘤疗法的特异性和效率，我们设计了一种多功能纳米平台，用于使用荧光（FL）和光声（PA）成像指导进行光化学疗法。由天然脂肪酸的低共熔混合物组成的纳米颗粒（NPs）在39°C时经历固-液相转变，用于包裹快速缺氧激活的前药替拉帕明（TPZ）和光敏剂IR780的材料。靶向肿瘤细胞的线粒体，可通过光动力疗法和光热疗法用于诱导低氧细胞死亡。在体外，当用NIR激光照射时，含有TPZ和IR7890的NPs表现出明显的细胞摄取并触发药物释放。体内在PA和FL成像指导和监测下，NPs的光化学疗法获得了最佳的抗肿瘤功效。通过将IR780线粒体靶向光疗与TPZ相结合，我们观察到了更高的抗肿瘤效果，并且有可能减轻传统化学疗法的副作用。在本文中，我们展示了一种新型的细胞内光化学疗法纳米系统，该系统共封装了光敏剂和缺氧激活药物，以精确而有效地增强总体抗肿瘤作用。
更新日期：2020-04-06
中文翻译：
用于线粒体靶向肿瘤协同治疗的光热低氧顺序可激活相变纳米剂。
为了提高抗肿瘤疗法的特异性和效率，我们设计了一种多功能纳米平台，用于使用荧光（FL）和光声（PA）成像指导进行光化学疗法。由天然脂肪酸的低共熔混合物组成的纳米颗粒（NPs）在39°C时经历固-液相转变，用于包裹快速缺氧激活的前药替拉帕明（TPZ）和光敏剂IR780的材料。靶向肿瘤细胞的线粒体，可通过光动力疗法和光热疗法用于诱导低氧细胞死亡。在体外，当用NIR激光照射时，含有TPZ和IR7890的NPs表现出明显的细胞摄取并触发药物释放。体内在PA和FL成像指导和监测下，NPs的光化学疗法获得了最佳的抗肿瘤功效。通过将IR780线粒体靶向光疗与TPZ相结合，我们观察到了更高的抗肿瘤效果，并且有可能减轻传统化学疗法的副作用。在本文中，我们展示了一种新型的细胞内光化学疗法纳米系统，该系统共封装了光敏剂和缺氧激活药物，以精确而有效地增强总体抗肿瘤作用。
京公网安备 11010802027423号